Pfizer Inc (PFE BE) stock market data APIs
€21.042
0.02(0.1%)
as of November 7, 2025
Try our APIs with
free plan!
Pfizer Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for PFE.BE.
Prev. Close
21.042
Open
21.0613
High
21.0613
Low
21.042
52 wk Range
18.1973-24.5
Market Cap
262 316 M
Dividends (Yield)
0.0336
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
On its third-quarter conference call held on Nov. 4, Pfizer PFE shed light on the two topics for which it has been in the news lately — the drug pricing deal with the Trump administration and the ba...
“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer
We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its t...
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite being on the market for around three years, Mounjaro and Zepbound have b...
Does Pfizer’s Recent Share Price Rebound Signal a New Opportunity in 2025?
Ever wondered if Pfizer is a hidden gem or just treading water in today’s market? Let’s jump in and get to the bottom of whether the stock is truly worth your attention right now. Pfizer’s share...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
